<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epigenetic silencing of regulatory genes by aberrant methylation contributes to <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>DNA methyltransferase inhibitors (DNMTI) represent promising new drugs for anti-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapies </plain></SENT>
<SENT sid="2" pm="."><plain>The DNMTI <z:chebi fb="0" ids="2038">5-Azacytidine</z:chebi> is effective against <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, but induces switching of latent to lytic Epstein-Barr virus (EBV) in vitro and results in EBV DNA demethylation with the potential of induction of lytic EBV in vivo </plain></SENT>
<SENT sid="3" pm="."><plain>This is of considerable concern given that recurrent lytic EBV has been linked with an increased incidence of EBV-associated <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Based on the distinct properties of action we hypothesized that the newer DNMTI <z:chebi fb="0" ids="46938">Zebularine</z:chebi> might differ from <z:chebi fb="0" ids="2038">5-Azacytidine</z:chebi> in its potential to induce switching from latent to lytic EBV </plain></SENT>
<SENT sid="5" pm="."><plain>Here we show that both <z:chebi fb="0" ids="2038">5-Azacytidine</z:chebi> and <z:chebi fb="0" ids="46938">Zebularine</z:chebi> are able to induce expression of E-cadherin, a cellular gene frequently silenced by hypermethylation in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, and thus demonstrate that both DNMTI are active in our experimental setting consisting of EBV-harboring Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> Akata cells </plain></SENT>
<SENT sid="6" pm="."><plain>Quantification of <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression of EBV genes revealed that <z:chebi fb="0" ids="2038">5-Azacytidine</z:chebi> induces switching from latent to lytic EBV and, in addition, that the immediate-early lytic <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> progresses to early and late lytic <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, <z:chebi fb="0" ids="2038">5-Azacytidine</z:chebi> induced upregulation of the latent EBV genes LMP2A, LMP2B, and EBNA2 in a similar fashion as observed following switching of latent to lytic EBV upon cross-linking of the B-cell receptor </plain></SENT>
<SENT sid="8" pm="."><plain>In striking contrast, <z:chebi fb="0" ids="46938">Zebularine</z:chebi> did not exhibit any effect neither on lytic nor on latent EBV gene expression </plain></SENT>
<SENT sid="9" pm="."><plain>Thus, <z:chebi fb="0" ids="46938">Zebularine</z:chebi> might be safer than <z:chebi fb="0" ids="2038">5-Azacytidine</z:chebi> for the treatment of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> in EBV carriers and could also be applied against EBV-harboring <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, since it does not induce switching from latent to lytic EBV which may result in secondary EBV-associated <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>